{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:47:39Z","timestamp":1792622859097,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40259-015-0144-3","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T12:18:33Z","timestamp":1445257113000},"page":"327-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast"],"prefix":"10.1007","volume":"29","author":[{"given":"Melinda","family":"Gooderham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,19]]},"reference":[{"key":"144_CR1","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583\u201390.","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"144_CR2","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","volume":"26","author":"PH Schafer","year":"2014","unstructured":"Schafer PH, Parton A, Capone LH, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016\u201329.","journal-title":"Cell Signal"},{"issue":"6","key":"144_CR3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1067\/mjd.2003.540","volume":"48","author":"DJ Najarian","year":"2003","unstructured":"Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn\u2019s disease. J Am Acad Dermatol. 2003;48(6):805\u201321.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"144_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187152807780077318","volume":"6","author":"W B\u00e4umer","year":"2007","unstructured":"B\u00e4umer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6(1):17\u201326.","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"2","key":"144_CR5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1165\/rcmb.2008-0091TR","volume":"39","author":"CH Serezani","year":"2008","unstructured":"Serezani CH, Ballinger MN, Aronoff DM, et al. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008;39(2):127\u201332.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"16","key":"144_CR6","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Beh\u00e7et\u2019s syndrome\u2014a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510\u20138.","journal-title":"N Engl J Med"},{"key":"144_CR7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","volume":"159","author":"PH Schafer","year":"2010","unstructured":"Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842\u201355.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"144_CR8","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1185\/030079908X301866","volume":"24","author":"AB Gottleib","year":"2008","unstructured":"Gottleib AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24(5):1529\u201338.","journal-title":"Curr Med Res Opin"},{"key":"144_CR9","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1021\/jm900210d","volume":"52","author":"HW Man","year":"2009","unstructured":"Man HW, Schafer P, Wong LM, et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1 H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem. 2009;52:1522\u20134.","journal-title":"J Med Chem"},{"issue":"22","key":"144_CR10","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","volume":"10","author":"MD Houslay","year":"2005","unstructured":"Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10(22):1503\u201319.","journal-title":"Drug Discov Today."},{"issue":"3","key":"144_CR11","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1111\/j.1468-3083.2012.04716.x","volume":"27","author":"KA Papp","year":"2013","unstructured":"Papp KA, Kaufmann R, Tha\u00e7i D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27(3):e376\u201383.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9843","key":"144_CR12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","volume":"380","author":"K Papp","year":"2012","unstructured":"Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomized controlled trial. Lancet. 2012;380(9843):738\u201346.","journal-title":"Lancet"},{"key":"144_CR13","doi-asserted-by":"crossref","unstructured":"Strand V, Hu A, Day R, et al. Improved quality of life with apremilast (APR) in the treatment of psoriasis: results from a phase IIb randomized controlled study (abstract no. P3337). J Am Acad Dermatol. 2011;64:AB154.","DOI":"10.1016\/j.jaad.2010.09.630"},{"issue":"8","key":"144_CR14","first-page":"888","volume":"12","author":"AB Gottlieb","year":"2013","unstructured":"Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013;12(8):888\u201397.","journal-title":"J Drugs Dermatol"},{"key":"144_CR15","unstructured":"Papp K, Reich K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1) [poster no. 8359]. In: Presented at the 72nd Annual Meeting of the American Academy of Dermatology; Denver; March 21\u201325, 2014."},{"key":"144_CR16","doi-asserted-by":"crossref","unstructured":"Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015. doi: 10.1111\/bjd.14164 .","DOI":"10.1111\/bjd.14164"},{"key":"144_CR17","unstructured":"Reich K, Soung J, Gooderham M, et al. Efficacy and safety of apremilast or etanercept compared with placebo in patients with moderate to severe psoriasis. In: Presented at the 73rd Annual Meeting of the American Academy of Dermatology; San Francisco; March 20\u201324, 2015."},{"issue":"6","key":"144_CR18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020\u20136.","journal-title":"Ann Rheum Dis"},{"key":"144_CR19","doi-asserted-by":"crossref","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42;479\u201388.","DOI":"10.3899\/jrheum.140647"},{"key":"144_CR20","unstructured":"Cutolo M, Myerson GE, Fleischmann RM, et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2) [presentation no. 815]. In: Presented at the 2013 ACR\/ARHP Annual Meeting; San Diego; October 26\u201330, 2013."},{"key":"144_CR21","doi-asserted-by":"crossref","unstructured":"Edwards CJ, Blanco FJ, Crowley J, et al. Long-term (52-Week) Results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3) [poster no. 311]. In: Presented at Presented at the 2013 ACR\/ARHP Annual Meeting; San Diego; October 26\u201330, 2013.","DOI":"10.1093\/rheumatology\/keu115.006"},{"key":"144_CR22","doi-asserted-by":"crossref","unstructured":"Edwards CJ, Wells AF, Adebajo AO, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-Week) improvements in enthesitis or dactylitis in patients with psoriatic arthritis: results from the PALACE 4 phase 3, randomized, controlled trial [poster no. SAT0389]. In: Presented at the Annual European Congress of Rheumatology (EULAR); Paris; June 11\u201314, 2014.","DOI":"10.1136\/annrheumdis-2014-eular.1574"},{"key":"144_CR23","doi-asserted-by":"crossref","unstructured":"Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of two phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2015 (In press).","DOI":"10.1016\/j.jaad.2015.09.001"},{"key":"144_CR24","unstructured":"Crowley J, Cather J, Gooderham M, et al. Apremilast in moderate to severe plaque psoriasis: 32-Week results in patients with nail, scalp, and palmoplantar involvement (ESTEEM 2) [poster no. P1687]. In: Presented at the 23rd Congress of the European Academy of Dermatology and Venereology; Amsterdam; October 8\u201312, 2014."},{"key":"144_CR25","unstructured":"Armstrong AW, Griffiths CEM, Tencer T, et al. Effect of apremilast on patient-reported outcomes in patients with moderate to severe plaque psoriasis in the ESTEEM 1 trial [poster no. P1691]. In: Presented at the 23rd Congress of the European Academy of Dermatology and Venereology; Amsterdam; October 8\u201312, 2014."},{"key":"144_CR26","unstructured":"Papp K, Zhang F, Tencer T, et al. The impact of apremilast therapy on work productivity among patients with moderate to severe plaque psoriasis: pooled analysis of 2 phase 3 studies [poster no. 1151]. In: Presented at the 73rd Annual Meeting of the American Academy of Dermatology; San Francisco; March 20\u201324, 2015."},{"key":"144_CR27","unstructured":"Crowley J, Gooderham M, Wasel N, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with nail, scalp, and palmoplantar psoriasis: 52-week results from the ESTEEM 2 trial [poster no. 894]. In: Presented at the 73rd Annual Meeting of the American Academy of Dermatology; San Francisco; March 20\u201324, 2015."},{"key":"144_CR28","unstructured":"Reich K, Papp K, Leonardi C, et al. Long\u2010term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from a Phase III, randomized, controlled trial (ESTEEM 1) [poster no.\u00a08296]. In: Presented at the 72nd Annual Meeting of the American Academy of Dermatology; Denver; March 21\u201325, 2014."},{"key":"144_CR29","unstructured":"Papp KA, Reich K, Sobell JM, et al. Two-year safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from a phase 3, randomized, controlled trial (ESTEEM 1) [poster no. 1055]. In: Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; San Francisco; March 20\u201324, 2015."},{"key":"144_CR30","unstructured":"Celgene Corporation. Otezla (apremilast): full prescribing information. http:\/\/www.otezla.com\/otezla-prescribing-information.pdf . Accessed Sept 2014."},{"key":"144_CR31","unstructured":"Reich K, Sobell J, Stevens RM, et al. Change in weight with apremilast, an oral phosphodiesterase\u00a04 inhibitor: pooled analysis of the ESTEEM\u00a01 and ESTEEM\u00a02 trials [poster no.\u00a0P1690]. Presented at the 23rd Congress of the European Academy of Dermatology and Venereology; Amsterdam; October 8\u201312, 2014."},{"issue":"8","key":"144_CR32","first-page":"891","volume":"146","author":"SK Kurd","year":"2010","unstructured":"Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891\u20135.","journal-title":"Arch Dermatol"},{"key":"144_CR33","doi-asserted-by":"crossref","unstructured":"Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;11:CD002309.","DOI":"10.1002\/14651858.CD002309.pub4"},{"issue":"2","key":"144_CR34","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1529-8019.2010.01312.x","volume":"23","author":"J Hayes","year":"2010","unstructured":"Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther. 2010;23(2):174\u201380.","journal-title":"Dermatol Ther"},{"key":"144_CR35","unstructured":"Menter A, Paul C, Stevens RM, et al. Psychiatric disorders and depression incidence with apremilast, an oral phosphodiesterase\u00a04 inhibitor: pooled analysis of the ESTEEM\u00a01 and ESTEEM\u00a02 trials [poster no.\u00a0P1689]. Presented at the 23rd Congress of the European Academy of Dermatology and Venereology; Amsterdam; October 8\u201312, 2014."},{"issue":"3","key":"144_CR36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","volume":"158","author":"JH Saurat","year":"2008","unstructured":"Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558\u201366.","journal-title":"Br J Dermatol"},{"issue":"5","key":"144_CR37","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","volume":"165","author":"J Barker","year":"2011","unstructured":"Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2011;165(5):1109\u201317.","journal-title":"Br J Dermatol"},{"issue":"17","key":"144_CR38","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","volume":"365","author":"K Reich","year":"2011","unstructured":"Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011;365(17):1586\u201396.","journal-title":"N Engl J Med"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-015-0144-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-015-0144-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-015-0144-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T18:07:20Z","timestamp":1567274840000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-015-0144-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["144"],"URL":"https:\/\/doi.org\/10.1007\/s40259-015-0144-3","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}